Oncolytics Biotech
ONCY
Oncolytics Biotech (ONCY) earnings history
Most recent quarter
- Fiscal period
- Q3 2025
- Period end
- Sep 30, 2025
- EPS actual
- −$0.10
- EPS estimate
- −$0.06
- EPS surprise
- −61.39%
- Revenue surprise
- +0.00%
- Revenue
- $0.00
- Revenue estimate
- $0.00
- Reported
- Nov 12, 2025
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q3 2025 | Nov 12, 2025 | −$0.06 | −$0.10 | −61.39% | $0.00 | SEC |
| Q2 2025 | Aug 8, 2025 | −$0.07 | −$0.05 | +30.08% | $0.00 | SEC |
| Q1 2025 | May 14, 2025 | −$0.07 | −$0.06 | +17.82% | $0.00 | SEC |
| Q4 2024 | Mar 7, 2025 | −$0.09 | −$0.07 | +20.09% | $0.00 | SEC |
| Q3 2024 | Nov 12, 2024 | −$0.07 | −$0.09 | −16.98% | $0.00 | SEC |
| Q2 2024 | Aug 1, 2024 | −$0.07 | −$0.07 | +3.48% | $0.00 | SEC |
| Q1 2024 | May 9, 2024 | −$0.08 | −$0.07 | +20.89% | $0.00 | SEC |
| Q4 2023 | Mar 7, 2024 | −$0.11 | −$0.04 | +65.52% | $0.00 | SEC |
| Q3 2023 | Nov 3, 2023 | −$0.08 | −$0.10 | −29.78% | $0.00 | SEC |
| Q2 2023 | Aug 14, 2023 | −$0.09 | −$0.09 | −1.14% | $0.00 | SEC |
| Q1 2023 | May 5, 2023 | −$0.09 | −$0.07 | +20.85% | $0.00 | SEC |
| Q4 2022 | Mar 3, 2023 | −$0.07 | −$0.10 | −43.24% | $0.00 | SEC |
| Q3 2022 | Nov 7, 2022 | −$0.08 | −$0.06 | +29.40% | $0.00 | — |
| Q2 2022 | Aug 11, 2022 | −$0.08 | −$0.07 | +13.27% | $0.00 | — |
| Q1 2022 | May 5, 2022 | −$0.11 | −$0.09 | +17.67% | $0.00 | — |
| Q4 2021 | Mar 3, 2022 | −$0.10 | −$0.11 | −8.72% | $0.00 | — |
| Q3 2021 | Nov 5, 2021 | −$0.11 | −$0.07 | +36.04% | $0.00 | — |
| Q2 2021 | Aug 6, 2021 | −$0.10 | −$0.10 | −4.66% | $0.00 | — |
| Q1 2021 | May 7, 2021 | −$0.14 | −$0.11 | +22.01% | $0.00 | — |
| Q4 2020 | Mar 5, 2021 | −$0.12 | −$0.17 | −42.06% | $0.00 | — |
Quarterly revenue
Frequently asked questions
When did Oncolytics Biotech (ONCY) last report earnings?
Oncolytics Biotech last reported on Nov 12, 2025, covering fiscal Q3 2025.
Did ONCY beat earnings estimates?
No. Oncolytics Biotech reported EPS of −$0.10 for Q3 2025 against a −$0.06 estimate — a 61.39% miss.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.